Featured Research

from universities, journals, and other organizations

Fighting cancer at your local Indian restaurant by eating curry

Date:
March 2, 2011
Source:
American Friends of Tel Aviv University
Summary:
Scientists have found that curcumin, an ingredient found in turmeric -- a bright yellow spice from south Asia and the main ingredient in curries -- can fight cancer when used in combination with a popular anti-inflammatory drug. Developing a new treatment with this finding, researchers have already had promising results in human clinical trials.

Turmeric, a bright yellow spice from south Asia belonging to the ginger family, is the main ingredient in curries -- and ancient wisdom suggests that it's also good for your health. Taking this wisdom to the laboratory, Tel Aviv University researchers have discovered that turmeric's active ingredient called curcumin amplifies the therapeutic activity of highly toxic anti-inflammatory drugs used to fight colon cancer when used at high doses.

Dr. Shahar Lev-Ari of Tel Aviv University's School of Public Health at the Sackler Faculty of Medicine and his colleagues have found that curcumin can fight cancer when used in combination with a popular anti-inflammatory drug, alleviating the inflammatory response caused when cancer takes root in the body. A treatment based on this finding has already had promising results in human clinical trials.

"Although more testing will be needed before a possible new drug treatment is developed," says Dr. Lev-Ari, "one could combine curcumin with a lower dose of a cancer anti-inflammatory drug, to better fight colon cancer." The results of the new study have been published in the journal Therapeutic Advances in Gastroenterology.

Alleviating unwanted side effects

Research in the last few decades has shown that cancer is linked to inflammation. Several lines of evidence demonstrate that chronic inflammation in the stomach can cause gastric cancer and that inflammation in the liver from hepatitis can lead to liver cancer.

Dr. Lev-Ari and his colleagues found that Celecoxib, a popular anti-inflammatory drug commonly used to treat arthritis, also inhibits proliferation of colon cancer in laboratory settings. Curcumin increases the anti-cancer and anti-inflammatory effects of Celecoxib while reducing its dose, thus reducing its toxic side-effects, including the rate of heart attack and stroke.

The effect of using a curcumin concentrate to improve the effects of cancer drugs was first proposed by Dr. Lev-Ari when he was a graduate student at Tel Aviv University's Sackler Faculty of Medicine under the supervision of Prof. Nadir Arber and Prof. Dov Lichtenberg.

Both co-supervisors were eager to test the possible health benefits described in folk medicine but were looking for hard evidence. "We would like to use this treatment for patients with all types of cancers," says Prof. Arber. "It has the promise of being an important life-extending therapy, particularly for non-curable pancreatic cancer, suggested by the very promising results we achieved for 20 pancreatic cancer patients."

Putting shelved cancer drugs back into circulation

Previous in vitro and in vivo experiments conducted by the Tel Aviv University team show that curcumin inhibits an enzyme known as COX-2 (cyclooxygenase-2), believed to cause inflammation. The team's research demonstrates that curcumin neutralizes oxygen free radicals, which are believed to play an important role in carcinogenesis.

These effects may be the basis for drug treatment of both inflammation and cancer through the combination of curcumin and Celecoxib. And it may also help return previously shelved potent anticancer drugs -- taken out of use due to high toxicity -- back to the market under lower dosage indications.


Story Source:

The above story is based on materials provided by American Friends of Tel Aviv University. Note: Materials may be edited for content and length.


Journal Reference:

  1. I. Aroch, S. Kraus, I. Naumov, E. Ron, S. Shapira, D. Kazanov, N. Giladi, A. Litvak, S. Lev-Ari, A. Hallak, I. Dotan, B. Shpitz, N. Arber. Chemopreventive effects of Coltect, a novel dietary supplement, alone and in combination with 5-aminosalicylic acid in 1,2-dimethylhydrazine-induced colon cancer in rats. Therapeutic Advances in Gastroenterology, 2010; 3 (5): 281 DOI: 10.1177/1756283X10379258

Cite This Page:

American Friends of Tel Aviv University. "Fighting cancer at your local Indian restaurant by eating curry." ScienceDaily. ScienceDaily, 2 March 2011. <www.sciencedaily.com/releases/2011/03/110302101744.htm>.
American Friends of Tel Aviv University. (2011, March 2). Fighting cancer at your local Indian restaurant by eating curry. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2011/03/110302101744.htm
American Friends of Tel Aviv University. "Fighting cancer at your local Indian restaurant by eating curry." ScienceDaily. www.sciencedaily.com/releases/2011/03/110302101744.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins